IP Library Granted Patent US 6,967,219
Granted Patent B2
US 6,967,219 · App. 10/268,106 · Granted Nov 22, 2005

Reversing or preventing premature vascular senescence

Assignees: Cornell Research Foundation, Inc.; The Research Foundation of the State University of New York
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,967,219
App. No.
10/268,106
Granted
Nov 22, 2005
Kind
B2
Abstract

Premature vascular senescence is reversed or prevented in tissue or cells by contacting the tissue or cells with a hydroxyguanidine. This finds application in treatment of patients with a disorder associated with elevated levels of advanced glycation end products in blood or tissue, e.g., patients with end stage renal disease or poorly controlled diabetes, and in contacting vascular tissue or cells ex vivo to prevent occurrence of premature senescence.

Claims (11)

1. A method of treating an animal with elevated levels of advanced glycation end products in blood or tissue comprising administering to the animal a therapeutically effective amount of agent which is selected from the group consisting of premature vascular senescence ameliorating hydroxyguanidines selected from the group consisting of hydroxy-L-arginine and hydroxyguanidine and pharmaceutically acceptable salts thereof

2. The method of claim 1 where the animal is affected with end stage renal disease.

3. The method of claim 1 where the animal is affected with poorly controlled diabetes.

4. The method of claim 1 where the animal is affected with chronic renal disease.

5. The method of claim 1 where the animal is affected with peripheral vascular disease.

6. The method of claim 1 where the animal is affected with systemic lupus erythematosis.

7. The method of claim 1 where the animal is affected with Alzheimer's disease.

8. The method of claim 1 where the animal is affected with a disorder selected from the group consisting of end stage renal disease, chronic renal disease, poorly controlled diabetes, peripheral vascular disease, systemic lupus erythematosis and Alzheimer's disease.

9. The method of claim 8 wherein the agent comprises hydroxy-L-arginine.

10. The method of claim 8 wherein the disorder is selected from the group consisting of end stage renal disease, chronic renal disease, perpheral vascular disease and systemic lupus erythematosis.

11. The method of claim 10 where the agent comprises hydroxy-L-arginine.

Assignments (5)
CONFIRMATORY LICENSE Recorded Jun 27, 2018
From: CORNELL UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046443/0792 →
CONFIRMATORY LICENSE Recorded Jul 29, 2010
From: CORNELL UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024758/0770 →
EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE Recorded Aug 25, 2008
From: CORNELL UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021434/0178 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2002
From: GROSS, STEVEN S.
To: CORNELL RESEARCH FOUNDATION, INC.
Reel/Frame 013510/0341 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2002
From: GOLIGORSKY, MICHAEL S.
To: RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK, THE
Reel/Frame 013510/0414 →
Continuity (2)
Provisional Application 6032885800 · Oct 12, 2001
Related Publication 20030073747A1 · Apr 17, 2003